Shares of Check Cap Ltd (NASDAQ:CHEK) have been given a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company.
Analysts have set a 12 month consensus target price of $10.50 for the company and are expecting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 98 out of 256 based on the ratings given to related companies.
CHEK has been the topic of several recent analyst reports. Dougherty & Co initiated coverage on shares of Check Cap in a report on Tuesday, February 5th. They issued a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research cut shares of Check Cap from a “hold” rating to a “sell” rating in a report on Tuesday, April 30th.
Check Cap (NASDAQ:CHEK) last posted its quarterly earnings results on Monday, May 13th. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03. On average, sell-side analysts predict that Check Cap will post -1.69 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its holdings in Check Cap by 96.0% in the first quarter. Wells Fargo & Company MN now owns 9,800 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 4,800 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Check Cap during the first quarter worth $89,000. Dimensional Fund Advisors LP raised its holdings in shares of Check Cap by 16.1% during the first quarter. Dimensional Fund Advisors LP now owns 40,773 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5,642 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Check Cap by 101.4% during the first quarter. Renaissance Technologies LLC now owns 247,442 shares of the medical research company’s stock worth $668,000 after purchasing an additional 124,600 shares during the period.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Featured Story: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.